Prevalence of the Genetic Mutation CYP2C8*5 in Selected Ethnic Groups in Southern Ghana

Charles Brown¹, Christopher Larbie²* and Dominic Selorm Yao Amuzu²

¹Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
²Department of Biochemistry and Biotechnology, College of Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

Authors’ contributions

This work was carried out in collaboration between all authors. Authors CB, CL and DSYA designed the study and wrote the protocol. Authors CB and CL supervised the work. Author DSYA carried out all laboratory works. Authors CL and DSYA performed the statistical analysis. Authors CB, CL and DSYA managed the analyses of the study. Authors CL and DSYA wrote the first draft of the manuscript. Author DSYA managed the literature searches. Authors CB, CL and DSYA edited the manuscript. All authors read and approved the final manuscript.

ABSTRACT

Aim: The study determined prevalence of clinically relevant CYP2C8*5 polymorphism in 80 unrelated individuals, from selected ethnic groups in Southern Ghana. Medical history on adverse drug reactions of the subjects and level of dependency on drugs metabolized by CYP2C8 enzyme was obtained by questionnaire. Allele Specific-PCR analyses were used to genotype CYP2C8*5 alleles in the study subjects.

Results: Allelic frequency for CYP2C8*5 was 83.75% which was statistically significant (p<0.05). There was no significant difference (p> 0.05) in the prevalence of CYP2C8*5 allele within the ethnic groups. Also, there was no significant association (p >0.05) between CYP2C8*5 allele and reported...
ADRs. Many (88.75%) of the study subjects depended highly (>1-3x in a year) on drugs metabolized by CYP2C8.

Conclusions: The high prevalence of CYP2C8*5 determined in the study population may indicate a high risk of toxicity in using drugs metabolized by CYP2C8 since CYP2C8*5 mutants have been reported to have a reduced enzymatic activity. This is the first reported study on prevalence of CYP2C8*5 in Ghanaians.

Keywords: CYP2C8 mutation; drug toxicity; artesunate amodiaquine; chloroquine; malaria.

1. BACKGROUND

Cytochrome P450 (CYP) family enzymes are diverse group of haemoproteins bound to membranes of the endoplasmic reticulum and mitochondria where they function in catalyzing the oxidative metabolism of many endogenous and exogenous compounds such as drugs and carcinogens [1]. Based on sequence homology, 57 isoforms of CYPs have been identified and classified in humans. CYPs are found in abundance in the liver and, to a lesser extent, in extra hepatic tissues such as the kidney, salivary ducts, intestine and adrenal cortical cells [2] as well as low expression of CYP2C8 protein in the intestines [3]. The CYP2C subfamily is responsible for catalyzing the metabolism of about 20% of clinically prescribed drugs. Cytochrome P450 2C8 (CYP2C8) is a member of the CYP2C subfamily and account for approximately 6% of the total CYP content in liver [4]. CYP2C8 plays important roles in the metabolism of about 5% of therapeutic drugs in phase I processes such as anti-malaria drugs (amodiaquine, chloroquine and dapsone); anti-cancer drug (paclitaxel) [5], anti-diabetes drugs (rosiglitazone, pioglitazone and repaglinide) [6,7]; antiarrhythmic drug (amiodarone) [8], and HMG-CoA reductase inhibitor (cerivastatin) [9]. Furthermore, CYP2C8 play a role in the metabolism of endogenous compounds such as lipids, steroidal hormones, retinoids and arachidonic acid [10-12]. The gene that code for the CYP2C8 enzyme is known as the CYP2C8 gene which is 31KB in size consisting of 9 exons [13]. It is located at chromosome 10q24 in a multigene cluster containing the other CYP2C subfamily members CYP2C9, CYP2C18 and CYP2C19 [14] prearranged as Cent–CYP2C18–CYP2C19–CYP2C9–CYP2C8–Tel [15]. The nucleotide sequences of CYP2C8 gene shares about 74% homology with CYP2C9 gene. The whole CYP2C gene family spans about 400 kb and has linkage between its genes [16]. The CYP2C8gene is polymorphic, and the distribution of variant alleles differs among ethnic populations. The wild-type gene of CYP2C8 is referred to as CYP2C8*1 (1A, 1B and 1C) and although there are about 15 identified variants of CYP2C8, studies have shown only CYP2C8*2, CYP2C8*3, CYP2C8*4 and CYP2C8*5 to have altered enzyme activity with respect to CYP2C8*1. CYP2C8*2 (c.805A>T, p.Ile269Phe) is the most common in blacks although it is very rare in Caucasians [17]. CYP2C8*3 (c.416G>A, p.Arg139Lys and c.1196A>G, p.Lys399Arg) results in the change in the amino acid sequence of CYP2C8 and is mostly found in Caucasians, with an allele frequency of approximately 10-20% [17]. There is a link between CYP2C9*2 (c.430C>T, p.Arg144Cys) and CYP2C8*3 variant alleles, where about 95% of phenotypes having the CYP2C8*3 variant allele have also been reported to be with the CYP2C9*2 variant allele [16]. CYP2C8*4 (c.792C>G, p.Ile264Met) allele is also present in Caucasians with a frequency of about 8% [17]. CYP2C8*5 results from a deletion of adenine (471) on exon 3 which lead to a frame shift in the mRNA which in turn leads to an early stop codon at residue 177 during protein synthesis (Bahdur, 2002). The resulting product of the enzyme lacks 64% of its normal protein structure affecting the haem-binding site and 5 out of 6 substrate recognition sites on the enzyme [18]. This implies that individuals homozygous for CYP2C8*5 who are poor metabolizers (PM) may find it difficult to tolerate drugs metabolized by CYP2C8 and suffer Adverse Drug Reactions [19].

Report indicates that the prevalence of CYP2C8*2 mutation was determined to be 16.75% in northern Ghanaiian populations [20] and 17% in Southern Ghanaians [21].

1.1 Aims

This study determined the allele frequency of CYP2C8*5 variant in selected ethnic groups in southern part of the Ghanaian population by estimating the distribution of CYP2C8*5 genotype frequencies in the Ashanti, Fanti, Anlo, Ewes and Ga ethnic groups in Southern Ghana. The study also determined association between
the CYP2C8*5 genotype and reported adverse drug reactions in the study subjects with respect to drugs metabolised by the enzyme. Finally the study determined the extent to which individuals with genotypes of the mutant allele depended on drugs metabolized by CYP2C8 enzyme.

2. MATERIALS AND METHODS

2.1 Ethical Issues

The research work was approved by the Committee on Human Research, Publications and Ethics, Kwame Nkrumah University of Science and Technology, School of Medical Sciences and Komfo Anokye Teaching Hospital, Kumasi-Ghana (CHRPE/AP/089/14). The participants were all fully briefed on the importance of the study and written informed consent was obtained from all the study subjects who participated in the research.

2.2 Study Design and Subjects

The study was cross-sectional involving 80 study subjects comprising of 40 males and 40 females with 10 subjects from each ethnic group being Akyem, Ashanti, Fanti, Eve, Anlo, Ga, Krobo and Nzema in Southern Ghana. They were healthy individual blood donors at Blood Units of Korle-Bu Teaching Hospital (Accra), Komfo Anokye Teaching Hospital Transfusion Medicine Unit (Kumasi), Hohoe Municipal Hospital (Hohoe) and Winneba Municipal Hospital (Winneba), who were willing to participate in the study. Only individuals whose grandparents are of the same ethnic background were considered for the study. Participation was entirely voluntary.

2.3 Blood Sample Collection

Peripheral blood samples were obtained from the study subjects and preserved on labelled Whatman No. 3 filter papers which were air dried and stored in plastic bags until DNA was extracted.

2.4 Medical History Data Collection Questionnaire

A questionnaire was also administered for information on medical history of the study subjects. They were asked if they have any history of adverse drug reactions and if yes then they indicate which drugs were involved. The study subjects were also given a list of common drugs metabolised by CYP2C8 enzyme and asked to indicate how often they use any of these drugs. The Body Mass Index of the study subjects was also obtained to reflect the health status of the study subjects.

2.5 Molecular Analysis

2.5.1 DNA extraction from blood blot samples

The genomic DNA was extracted from the filter paper blood blots collected using the TE buffer extraction method [22]. The extract DNA was stored at -40°C in the DNA microtubes in a Deep freezer until use after quantification using spectrophotometric analyses.

2.5.2 AS-PCR A475 del (Frameshift, CYP2C8*5)

Allele specific (AS) PCR analysis was used for the analysis of A475 del (Frameshift, CYP2C8*5) with the primers 5'-AGG CAA TTC CCC AAT ATC TC-3' (3S) and 5'-TCA CCC ACC CTT GGT TTT C-3' (mutant) [18]. The DNA was amplified in 20 µl reaction mix containing 1X PCR buffer (invitrogen, USA), 25 mM MgCl$_2$ (Promega, USA), 10 mM DNTP mix containing each of the four different forms of deoxyribonucleotide triphosphates (DNTPs), 10µM of the primers 5'-AGG CAA TTC CCC AAT ATC TC-3' (3S), 5'-TCA CCC ACC CTT GGT TTT C-3' (mutant) [18] and 5U/µl of DNA Taq Polymerase. An amount of 5 µl extracted genomic DNA was used as template for the PCR reaction. Sterile double distilled water (sddH$_2$O) was added to the mix to make the volume up to 20 µl. For each reaction, a non-DNA negative control and positive control containing the expected DNA was also used in the set up. The PCR was run in Gene Amp PCR System 9700 thermo-cycler using cycling conditions as follows: initial denaturation (94°C for 4 minutes), followed by 40 cycles of denaturing (94°C for 1 minute), Annealing (51°C at 1 minute), Extension (72°C for 2 minutes) and Final Extension of cycle (72°C for 7 minutes). The final reaction volume of 20µl contained 8-10 µl of the amplified products. The PCR machine was set keep the PCR products at 4°C until they were removed from thermo-cycler for storage and further analysis.

2.5.3 Gel electrophoresis

The PCR products were electrophoresed in 2% agarose gels prepared with 1x TAE buffer and stained with 0.5 µg/ml ethidium bromide dye.
About 8 µl of each sample of DNA was added to 1 µl of 10x bromothymol blue gel loading dye. The gels were run in a 1x TAE buffer at 100V for 45 minutes using mini gel system (BIORAD, USA), visualized by ultraviolet transillumination and photographed using a Sony Toyobo FASIII gel documentation system. The sizes of the PCR products were calculated using the mobility of a 100bp molecular weight ladder of DNA (Promega, USA) as the reference.

2.6 Statistical Analysis

For the analysis of the data Chi-square ($\chi^2$) and Student t-test analyses were performed with SPSS version 20.0 using a confidence interval of 5% and graph plotted using Microsoft Excel version 2007.

3. RESULTS

3.1 Demographics of Study Subjects

The age distribution of the study subjects ranged from 18 to 53 years with an average age of 30.63±8.75 years. Majority of the study subjects had access to secondary (45%) and tertiary education (42.5%). The Body Mass Index (BMI) distribution of the subjects ranged from 15.78 kg/m$^2$ to 36.75 kg/m$^2$ with a mean of 22.36±3.20 kg/m$^2$.

3.2 Distribution of BMI of Study Subjects

Statistically, there was no significant difference between the study subjects when their BMI was cross tabulated against presence or absence of the CYP2C8*5 mutant allele ($p>0.05$).

3.3 Genotyping of CYP2C8*5 and Ethnic Distribution

DNA was extracted from all the samples ($n=80$) and PCR was performed on the DNA samples using primers specific for amplifying mutant allele of CYP2C8*5. Fig. 1 is an ethidium bromide stained agarose gel electrophoregram showing the positive and negative samples.

The study determined the prevalence of CYP2C8*5 allele as 83.75% (Table 2). There was no significant difference between the selected ethnic groups with respect to the observed prevalence of CYP2C8*5 in the study population ($p>0.05$) (Table 2).

3.4 Adverse Drug Reactions and CYP2C8*5 Mutant Allele Status

Table 3a shows reported history of adverse drug reactions by the study subjects. Thirty-three (41.25%) of the respondents indicated they had a history of adverse drug reaction, while 4 (5%) were not sure whether they had a history of adverse drug reaction. Table 3a further shows the drugs involved in the adverse drug reactions among the study subjects. Eighteen (22.5%) of the study subjects reported that they have reacted to Chloroquine CQ, while 4 (5%) reacted to only Amodiaquine (AQ) and 5 (6.25%) reacted to both CQ and AQ.

Table 3b shows the cross tabulation of CYP2C8*5 against reported history of adverse drug reaction. The study subjects reported that they react to the drugs Chloroquine and Amodiaquine (both antimalarial drugs) as well as Aspirin. Statistically, there was no significant association between having CYP2C8*5 allele and reported history of adverse drug reactions ($p>0.05$).

3.5 Extent of Dependency on Drugs Metabolized by CYP2C8 Enzymes

In generally many of the study subjects (88.75%) depend highly (1-3x in the past 5 years) on drugs metabolized by the CYP2C8 enzyme (Table 4). There was no significant association between the presence of the CYP2C8*5 mutant allele and reported history of adverse drug reactions ($p>0.323$).

| BMI status   | CYP 2C8*5 mutant allele status | P-value |
|--------------|--------------------------------|---------|
|              | Presence (%) | Absence (%) |         |
| <18.50       | 3 (4.54)     | 2 (14.28)   |         |
| 18.50 - 24.90| 54 (81.81)   | 8 (57.1)    |         |
| 25.00 - 29.90| 9 (13.63)    | 2 (14.28)   |         |
| >=30.00      | 0 (0)        | 2 (14.28)   |         |
| Total        | 66 (83.75)   | 14 (16.25)  | 0.007   |
Fig. 1. Ethidium bromide stained 2.0% agarose gel electrophoregram showing PCR amplified DNA sequences of CYP2C8*5 for the Ashanti Male Subjects

Table 2. Frequency of CYP2C8*5 distribution in study population

| Ethnicity | Positive CYP2C8*5 mutants (%) | P-value |
|-----------|--------------------------------|---------|
|           | Females (5)                    | Males (5) | Overall (10) |
| Akyem     | 3 (60)                         | 5 (100)   | 8 (80)       |
| Ashanti   | 4 (80)                         | 4 (80)    | 8 (80)       |
| Fanti     | 3 (60)                         | 4 (80)    | 7 (70)       |
| Anlo      | 4 (80)                         | 4 (80)    | 8 (80)       |
| Eve       | 4 (80)                         | 5 (100)   | 9 (90)       |
| Ga        | 5 (100)                        | 5 (100)   | 10 (100)     |
| Krobo     | 5 (100)                        | 5 (100)   | 10 (100)     |
| Nzema     | 2 (40)                         | 5 (100)   | 7 (70)       |
| **Total (80)** | **30 (75)**            | **37 (92.5)** | **67 (83.75)** | **0.636** |

Table 3a. History of adverse drugs reactions and drugs involved

| Variable                          | Category       | Frequency (%) | p-value |
|-----------------------------------|----------------|---------------|---------|
| History of adverse drug reaction  | Yes            | 33 (41.25)    | **0.000** |
| by study subjects                 | No             | 43 (53.75)    |         |
|                                   | Not Sure       | 4 (5)         |         |
| **Total**                         |                | **80 (100)**  |         |
| Drugs reacted to by study subjects| Amodiaquine (AQ)| 4 (5)        |         |
|                                   | Chloroquine (CQ)| 18 (22.5)   |         |
|                                   | CQ and AQ      | 5 (6.25)      |         |
|                                   | Aspirin        | 1 (1.25)      |         |
|                                   | Other          | 6 (7.5)       |         |
| **Total**                         |                | **33 (41.25)**|         |

Table 3b. CYP2C8*5 mutant allele and history of adverse drug reactions

| CYP 2C8*5 status | History of adverse drug reaction | Total | p-value |
|------------------|---------------------------------|-------|---------|
|                  | Yes (%)                         | No (%)| Not Sure (%)|
| Presence         | 25 (37.87)                      | 37 (56.06) | 4(6.06) | 66 |
| Absence          | 8 (57.1)                        | 6 (42.86) | 0(0)   | 14 |
| **Total**        | **33 (41.25)**                  | **43 (53.75)** | **4(5.0)** | **80(100)** | **0.323** |
Table 4. Extent of dependency on drugs metabolized by CYP2C8 in past 5 years

| Extent of dependency on CYP2C8 drugs substrates in 5 years (%) | Category | Frequency (%) | P-value |
|--------------------------------------------------------------|----------|---------------|---------|
|                                                               | 0x       | 9 (11.25)     |         |
|                                                               | 1-3x     | 69 (86.25)    |         |
|                                                               | 4-6x     | 2 (2.50)      |         |
|                                                               | 7-9x     | 0 (0.00)      |         |
|                                                               | >10x     | 0 (0.00)      |         |
|                                                               | Total    | 80 (100)      | 0.000   |

4. DISCUSSION

4.1 Distribution of CYP2C8*5 Genotype

The overall prevalence of CYP2C8*5 observed in the study population was 83.75%. This was higher compared to that observed in the Japanese population as 2.5% involving 200 healthy subjects [18] and Soyama, Saito [23] who also reported the heterozygote of CYP2C8*5 in Japanese population to be 0.9% involving 54 subjects. Apart from the Japanese population, there is not much information on the allele frequency of CYP2C8*5 in other populations. The prevalence of CYP2C8*5 observed is also higher than the reported prevalence of CYP2C8*2 (16-17.0%) in the same Ghanaian population [20,21]. The result of this study supports and augments the findings that CYP2C8 gene mutation is high in the Ghanaian population. In addition, the observed prevalence (83.75%) of CYP2C8*5 in the study is higher than other reported CYP2C8 gene mutations in the African population such CYP2C8*2 (12.0%) in Burkinabes [24]. It is also higher than CYP2C8*2 (21.0%), CYP2C8*3 (2.1%) and CYP2C8*4 (0.6%) reported by Cavaco, Stromberg-Norklit [25] in 165 paediatric malaria patients in Zanzibar Islands which has a mixed race population of both Arabs and Asians.

There was no significant difference between the selected ethnic groups with respect to the observed prevalence of CYP2C8*5 in the study population (p>0.05) (Table 2) As such, the information from some of these ethnic populations may be useful on populations or individuals that share a close blood relation with those in the selected study populations but are outside Ghana such as the Ewes whose population extend from Ghana through Togo and Benin to Nigerian and Cameroun. These also include the Nzemas, Fantis and Ashantis whose population extends into Ivory Coast as well as individuals abroad.

4.2 Distribution of BMI and CYP2C8*5

Most the participants having healthy BMI (Table 1) is a reflection of their health status as well the ability to dose drugs correctly. There are medications which accumulate in adipose tissue and will necessitate an adjusted weight for a better accurate dosing for such drugs since not all the drugs are bioavailable. An adjusted, or dosing weight, is calculated to account for obese patients exceeding >125% of their ideal body weight [26-28]. Individuals who are underweight are less likely to tolerate drug while individuals who are overweight are prone to experiencing therapeutic failure and will require more dosage compared to the normal weight individuals. Despite the healthy BMI in the study population, individuals may still be at risk of having adverse reactions from normal dosing of drugs since the calculation for the dosing does not take into consideration the high prevalence of the CYP2C8*5 mutation observed. Rather dosing is based on the assumption that the population has normal individuals having the correct CYP2C8 wild type allele.

4.3 Adverse Drug Reaction and CYP2C8*5n

The study population resides in an area where malaria is endemic with 3,415,912 confirmed cases in 2013 [29, p. 119]. As such most of the study subjects who have them use antimalarial drugs such as Amodiaquine and Chloroquine which they have a history of adverse reaction. Antimalarial treatment courses distributed as a proportion of estimated malaria cases in the public sector in 2014 was 100% for Ghana [29, p. 69]. The WHO recommended treatment for uncomplicated malaria is the artemisinin-based combination therapy (ACT) which most of the study subjects have been using to combat malaria [30, p. 9].

Considering the structure of protein product of CYP2C8*5 and the lack of enzyme activity, it would have been expected that majority of the study subjects would report a history of adverse drug reactions but this was not observed in the study. This implies that the study subjects could be heterozygous individuals with one correct allele (CYP2C8*1) and one mutant allele (CYP2C8*5) or they could even have two different mutant alleles (CYP2C8*2 and
CYP2C8*5) such that the activity of the enzyme is still present but at reduced levels. With previous works conducted indicating that CYP2C8*2 is the most predominant (17%) of CYP2C8 mutation in the Ghanaian population, this is more likely to be the case.

Also some drug substrate have multiple enzymes involved in their metabolism [31]. The similarity in size accounts partly for the observation of CYP2C8 and CYP3A4 having many related substrates compared to other CYPs [32]. Hence although the frequency of CYP2C8*5 was observed to be high in the population, if the wild type of another enzyme which metabolizes the same drug is present, the effect of the active enzyme will mask the absence of activity of the other enzyme to some extent. Studies conducted in Ghana however observed that individuals using Artesunate Amodiaquine, when it was first introduced were having Adverse drug reactions [33]. Nevertheless, due to the heterozygosity of CYP2C8 gene, individuals having the CYP2C8*5 may still produce a functional enzyme from the non-mutant CYP2C8*5 allele and tolerate certain drugs. Such individuals are still at risk of drug toxicity since most of those heterozygous for the mutation will be considered as partial metabolizers. Such individual will have both a functional and non-functional enzymes.

4.4 Extent of Dependency on Drugs Metabolized by CYP2C8 Enzyme

Although there was no significant association between the presence of the CYP2C8*5 mutant allele and reported history of adverse drug reactions (p >0.323), the study population may be at risk of using drugs metabolised by CYP2C8 enzyme. This may be true considering the high presence of the CYP2C8*5 allele in the study population and the high level of dependence on drugs metabolized by CYP2C8 by the study subjects.

5. CONCLUSIONS

The prevalence of CYP2C8*5 mutant allele in selected ethnic groups in Southern Ghana is high (83.75%). There was no significant difference in the prevalence of CYP2C8*5 allele between the selected ethnic groups being Ashanti, Akem, Fanti, Ewe, Anlo, Ga, Krobo and Nzema. Also there was no significant association between individuals with CYP2C8*5 mutant allele and reported history of adverse drug reactions. Much of the study subjects (88.75%) depend highly (>1-3x in year) on drugs metabolized by CYP2C8. The study population may be at risk of using drugs metabolised by CYP2C8 although no statistically significant association between presence of the CYP2C8*5 allele and reported history of ADRs (p >0.323) was observed in the study.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Redlich G, Zanger UM, Riedmaier S, Bache N, Giessing AB, Eisenacher M, et al. Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. Journal of Proteome Research. 2008;7(11):4678-88. PubMed PMID: 18828626

2. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2004;52(4):447-54. PubMed PMID: 15033996

3. Lapple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003;13(9):565-75. PubMed PMID: 12972955

4. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT. Abundance of cytochromes P450 in human liver: A meta-analysis. Br J Clin Pharmacol. 2004;57:687-8.

5. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Research. 1994;54(21):5543-6. PubMed PMID: 7923194

6. Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokuo T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone.
Xenobiotica; the fate of foreign compounds in biological systems. 2000;30(1):61-70.
PubMed PMID: 10699591

7. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999;48(3):424-32.
PubMed PMID: 10510156
PubMed Central PMCID: 2014317

8. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: An approach to predict the contribution with relative activity factor. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 2000;28(11):1303-10.
PubMed PMID: 11038157

9. Muck W. Clinical pharmacokinetics of cerivastatin. Clinical Pharmacokinetics. 2000;39(2):99-116.
PubMed PMID: 10976657

10. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Archives of Biochemistry and Biophysics. 1996;330(1):87-96.
PubMed PMID: 8651708

11. Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochemical Pharmacology. 1999;58(7):1201-8.
PubMed PMID: 10484078

12. Capdevila J, Chacos N, Werringloer J, Prough RA, Estabrook RW. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proceedings of the National Academy of Sciences of the United States of America. 1981;78(9):5362-6.
PubMed PMID: 6795631
PubMed Central PMCID: 348745

13. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. Journal of Biochemical and Molecular Toxicology. 1999;13(6):289-95.
PubMed PMID: 10487415

14. Finta C, Zaphiropoulos PG. The human CYP2C locus: A prototype for intergenic and exon repetition splicing events. Genomics. 2000;63(3):433-8.
PubMed PMID: 10704292

15. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995;28(2):328-32.
PubMed PMID: 8530044

16. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochemical and Biophysical Research Communications. 2002;299(1):25-8.
PubMed PMID: 12435384

17. Totah RA, Rettie AE. Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance. Clinical pharmacology and therapeutics. 2005;77(5):341-52.
PubMed PMID: 15900280

18. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 2003;31(6):687-90.
PubMed PMID: 12756196

19. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11(7):597-607.
PubMed PMID: 11668219

20. Rower S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah RN, et al. Short communication: High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Tropical medicine & international health: TM & IH. 2005;10(12):1271-3.
PubMed PMID: 16359408

21. Kudzi W, Dodo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Medical Genetics. 2009;10:124.
PubMed PMID: 19954515
PubMed Central PMCID: 3224726

22. Plowe CV, Djimde A, Bouaie M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: Polymerase chain reaction methods for surveillance in Africa. The American Journal of Tropical Medicine and Hygiene. 1995;52(6):565-8.
PubMed PMID: 7611566
23. Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metabolism and Pharmacokinetics. 2002;17(4):374-7. PubMed PMID: 15618689

24. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa. Clinical Pharmacology and Therapeutics. 2007;82(2):197-203. PubMed PMID: 17361129

25. Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. European Journal of Clinical Pharmacology. 2005;61(1):15-8. PubMed PMID: 15785959

26. Wurtz R, Itoh TS, Rodvold K. Antimicrobial dosing in obese patients. Clinical Infectious Diseases. 1997;25(1):112-8.

27. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. Journal of Pharmaceutical Sciences. 1999;88(1):1-7.

28. Cheymol G. Effects of obesity on pharmacokinetics. Clinical Pharmacokinetics. 2000;39(3):215-31.

29. WHO. World malaria report 2015. Geneva: World Health Organization. 2015;34:244.

30. WHO. Guidelines for the treatment of malaria, third edition. Geneva: World Health Organization. 2015;313.

31. Glamočlija U, Jevrić-Čaušević A. Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics. Acta Pharm. 2010;60(4):387-406.

32. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: Potential for interactions with CYP2C8 inhibitors. Basic, Clinical Pharmacology & Toxicology. 2006;99(1):44-51.

33. Adjei G, Goka B, Rodrigues O, Høgberg LCG, Alifrangis M, Kurtzhals J. Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose. Ghana Medical Journal. 2009;43(3).